Abstract: There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilizing the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.

Abstract: There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilising the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.

Abstract: There is disclosed agents capable of inhibiting the binding of a MAP kinase to a binding domain of an integrin for the MAP kinase, and methods of modulating the activity of a cell utilising the agents. The methods are particularly suitable for inhibiting the growth of cancer cells.

Abstract: Dislosed is the integrin-binding domain of MAP kinase. Interaction between MAP kinase and integrin via this domain activates MAP kinase and initiates cellular activity. Methods of modulating cellular activity by inhibiting direct MAP kinase-integrin binding are provided. These methods have particular use in inhibiting growth of cancer cells.

Abstract: This invention describes a new antibiotic, hereinafter designated as bushrin, having the formula C16H16O2, which is 7-(3-furyl)-3,7-dimethyl-7,8-dihydro-1-naphthalenol, its production method by fermentation, and the methods related to its recovery, concentration and purification from the crude solutions. The invention includes within its scope the agent in dilute form, as a crude concentrate, and in pure form. The invention also relates to the use of the compound according to the invention in antimicrobial compositions and as antiseptics or disinfectants.

Abstract: The present invention relates to methods of detecting, monitoring the efficacy of treatment of, and assessing the severity of ovarian cancer, by assessing the concentration of haptoglobin-1 precursor in a sample of biological fluid. The invention also relates to a kit comprising an antibody or nucleic acid probe specific for haptoglobin-1 precursor for use in the diagnosis of ovarian cancer, monitoring the efficacy of treatment of ovarian cancer, or assessing the severity of ovarian cancer.

Abstract: The present invention relates to a cell-free immunoreactive Integrin Linked Kinase which is present in samples of biological fluids from patients suffering from ovarian cancer. The invention also relates to methods of diagnosis, screening, monitoring treatment and treatment of cancers, especially ovarian cancer, and to kits and compounds for use therein.

Abstract: Dislosed is the integrin-binding domain of MAP kinase. Interaction between MAP kinase and integrin via this domain activates MAP kinase and initiates cellular activity. Methods of modulating cellular activity by inhibiting direct MAP kinase-integrin binding are provided. These methods have particular use in inhibiting growth of cancer cells.